Sterling Capital Management LLC Sells 106,238 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Sterling Capital Management LLC decreased its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 37.6% in the 3rd quarter, HoldingsChannel reports. The fund owned 176,512 shares of the company’s stock after selling 106,238 shares during the period. Sterling Capital Management LLC’s holdings in Teva Pharmaceutical Industries were worth $6,990,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently modified their holdings of the company. Cornerstone Planning Group LLC lifted its position in shares of Teva Pharmaceutical Industries by 547.1% in the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock worth $27,000 after acquiring an additional 755 shares during the period. Root Financial Partners LLC bought a new stake in shares of Teva Pharmaceutical Industries during the third quarter valued at approximately $33,000. Western Wealth Management LLC bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at approximately $43,000. Sunbelt Securities Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at $45,000. Finally, EverSource Wealth Advisors LLC lifted its position in Teva Pharmaceutical Industries by 64.0% in the first quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company’s stock worth $50,000 after purchasing an additional 647 shares during the period. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA opened at $39.39 on Friday. Teva Pharmaceutical Industries Ltd. has a twelve month low of $18.88 and a twelve month high of $42.02. The firm has a market cap of $45.90 billion, a PE ratio of 65.65, a price-to-earnings-growth ratio of 3.66 and a beta of 0.89. The company has a debt-to-equity ratio of 1.56, a quick ratio of 0.67 and a current ratio of 0.88. The business has a fifty day moving average of $38.67 and a 200-day moving average of $35.27.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. The business had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. On average, equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.00 EPS for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Brian Savage sold 7,342 shares of the business’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $38.85, for a total value of $285,236.70. Following the completion of the transaction, the insider directly owned 8,500 shares of the company’s stock, valued at approximately $330,225. The trade was a 46.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Roberto Mignone sold 367,600 shares of the business’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $39.06, for a total transaction of $14,358,456.00. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 374,959 shares of company stock worth $14,644,285. Insiders own 0.54% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on TEVA. UBS Group lifted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a research note on Friday, September 4th. Leerink Partners started coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 price target on the stock. Oppenheimer increased their price objective on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, October 9th. Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the stock an “overweight” rating in a report on Thursday, October 15th. Finally, Zacks Research downgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $46.08.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world’s largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva’s portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.